Date: 2014-03-11
Type of information: R&D agreement
Compound: anti-inflammatory small molecules
Company: Sanofi (France) UCB (Belgium)
Therapeutic area: Immunological diseases - Inflammatory diseases - Autoimmune diseases
Type agreement: R&D
Action mechanism:
Disease:
Details: * On March 11, 2014, UCB and Sanofi have entered into a scientific and strategic collaboration for the discovery and development of innovative anti-inflammatory small molecules which have the potential to treat a wide range of immune-mediated diseases in areas such as gastroenterology and arthritis. UCB NewMedicines, the research arm of UCB, have used an innovative approach to identify small molecules modulators of a biological pathway, for which parenterally administered biologic therapies have proven highly efficacious in patients. A dedicated team of scientists will be formed under the leadership of Sanofi and UCB, and will join forces in a discovery and development based collaboration to characterize and identify new potential therapies.
Financial terms: Under the terms of the agreement, Sanofi and UCB will share costs and profits on a 50/50 basis. UCB will be entitled to initial upfront, preclinical and clinical development milestone payments from Sanofi, potentially exceeding € 100 million.
Latest news:
